JP2009528987A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528987A5
JP2009528987A5 JP2008553534A JP2008553534A JP2009528987A5 JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5 JP 2008553534 A JP2008553534 A JP 2008553534A JP 2008553534 A JP2008553534 A JP 2008553534A JP 2009528987 A5 JP2009528987 A5 JP 2009528987A5
Authority
JP
Japan
Prior art keywords
protein
yeast
influenza
antigen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008553534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528987A (ja
JP5198290B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/061572 external-priority patent/WO2007092792A2/en
Publication of JP2009528987A publication Critical patent/JP2009528987A/ja
Publication of JP2009528987A5 publication Critical patent/JP2009528987A5/ja
Application granted granted Critical
Publication of JP5198290B2 publication Critical patent/JP5198290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008553534A 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン Expired - Fee Related JP5198290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
US60/765,025 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012260860A Division JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物

Publications (3)

Publication Number Publication Date
JP2009528987A JP2009528987A (ja) 2009-08-13
JP2009528987A5 true JP2009528987A5 (OSRAM) 2010-04-02
JP5198290B2 JP5198290B2 (ja) 2013-05-15

Family

ID=38345897

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008553534A Expired - Fee Related JP5198290B2 (ja) 2006-02-02 2007-02-02 免疫反応を誘発する酵母ベースワクチン
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012260860A Pending JP2013075899A (ja) 2006-02-02 2012-11-29 治療用組成物
JP2014230982A Withdrawn JP2015038147A (ja) 2006-02-02 2014-11-13 免疫反応を誘発する酵母ベースワクチン

Country Status (14)

Country Link
US (2) US7736642B2 (OSRAM)
EP (2) EP1988919A4 (OSRAM)
JP (3) JP5198290B2 (OSRAM)
KR (2) KR20140029551A (OSRAM)
CN (2) CN101405026B (OSRAM)
AU (1) AU2007212076B2 (OSRAM)
BR (1) BRPI0706913A2 (OSRAM)
CA (1) CA2638815A1 (OSRAM)
IL (2) IL193196A (OSRAM)
IN (1) IN2014DN08830A (OSRAM)
MX (1) MX2008009929A (OSRAM)
SG (2) SG169375A1 (OSRAM)
TW (2) TW201412329A (OSRAM)
WO (1) WO2007092792A2 (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
MX2008009929A (es) * 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
EP1998814A4 (en) * 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
CA2657849A1 (en) * 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
EP2419126B1 (en) * 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
CA2762044A1 (en) * 2009-05-18 2010-11-25 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
JP5913103B2 (ja) 2009-09-14 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
AU2011312178B2 (en) * 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2627774B1 (en) * 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EP2670430B1 (en) * 2011-01-31 2015-04-01 Baxter International Inc Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
AU2012228937B2 (en) * 2011-03-17 2016-11-03 Globeimmune, Inc. Yeast-Brachyury immunotherapeutic compositions
WO2012162342A2 (en) * 2011-05-23 2012-11-29 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
BR112013032381B1 (pt) * 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
RU2017143985A (ru) 2011-08-17 2019-02-14 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
ES2525205T3 (es) 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
US11105802B2 (en) * 2012-12-10 2021-08-31 Seattle Children's Hospital Cell-free biofragment compositions and related systems, devices, and methods
CN105209063A (zh) * 2013-03-15 2015-12-30 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素-23的疫苗
WO2014186047A1 (en) 2013-03-19 2014-11-20 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
EP4070818A3 (en) * 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
KR102409372B1 (ko) * 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
CA2995454A1 (en) * 2015-08-11 2017-02-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
WO2017222619A2 (en) 2016-03-24 2017-12-28 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
WO2018200389A1 (en) 2017-04-24 2018-11-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
CN111315407B (zh) 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020061203A1 (en) 2018-09-21 2020-03-26 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CA3138174A1 (en) * 2019-05-21 2020-11-26 David James O'hagan Yeast-based oral vaccination
KR20220152226A (ko) * 2020-02-11 2022-11-15 사이토누스 테라퓨틱스, 인크. 신속한 백신 플랫폼
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
EP0733113B1 (en) * 1994-01-11 2007-05-02 Vlaams Interuniversitair Instituut voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1294892B1 (en) * 2000-06-23 2007-10-17 Wyeth Holdings Corporation Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
AU2005248361B2 (en) * 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
MX2008009929A (es) * 2006-02-02 2008-10-01 Globeimmune Inc Vacuna a base de levadura para inducir una respuesta inmune.

Similar Documents

Publication Publication Date Title
JP2009528987A5 (OSRAM)
Pardi et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses
Freyn et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
US11938221B2 (en) Multivalent nanoparticle-based vaccines
Wohlbold et al. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses
IL193196A (en) The total vaccine carried yeast and the protein of fusion of the influenza virus
Gerhard et al. Prospects for universal influenza virus vaccine
Song et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity
Branco et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
Deng et al. M2e-based universal influenza A vaccines
Li et al. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates
Gao et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
Deliyannis et al. Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus
Lee et al. Mechanisms of cross-protection by influenza virus M2-based vaccines
Arunkumar et al. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
JP2014507144A5 (ja) 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
Du et al. Flu universal vaccines: new tricks on an old virus
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Mbewana et al. Production of H5N1 influenza virus matrix protein 2 ectodomain protein bodies in tobacco plants and in insect cells as a candidate universal influenza vaccine
Choi et al. Chromatographically-purified capsid proteins of red-spotted grouper nervous necrosis virus expressed in Saccharomyces cerevisiae form virus-like particles
Bolduc et al. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses
Hoxie et al. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Prokopenko et al. Truncation of NS1 protein enhances T Cell-mediated cross-protection of a live attenuated influenza vaccine virus expressing wild-type nucleoprotein